Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB – Research Report), Harvard Bioscience (HBIO – Research Report) and Disc Medicine (IRON – Research Report).
Biogen (BIIB)
In a report released today, Steve Chesney from Atlantic Equities maintained a Hold rating on Biogen, with a price target of $282.00. The company’s shares closed last Tuesday at $282.41.
According to TipRanks.com, Chesney is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $325.11 average price target, representing an 11.7% upside. In a report issued on April 17, Wedbush also maintained a Hold rating on the stock with a $263.00 price target.
See today’s best-performing stocks on TipRanks >>
Harvard Bioscience (HBIO)
KeyBanc analyst Paul Knight maintained a Buy rating on Harvard Bioscience today and set a price target of $7.00. The company’s shares closed last Tuesday at $5.25, close to its 52-week high of $5.90.
According to TipRanks.com, Knight is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harvard Bioscience with a $7.00 average price target, implying a 40.6% upside from current levels. In a report released today, Benchmark Co. also maintained a Buy rating on the stock with a $7.00 price target.
Disc Medicine (IRON)
Wedbush analyst David Nierengarten maintained a Buy rating on Disc Medicine today and set a price target of $36.00. The company’s shares closed last Tuesday at $30.05, close to its 52-week high of $32.85.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $37.17 average price target, which is a 26.2% upside from current levels. In a report issued on April 20, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48
- Biogen reports Q1 EPS $3.40, consensus $3.28
- Biogen price target raised to $300 from $295 at BofA
- Agios Pharmaceuticals appoints Capello to board of directors
